GFAP levels are significantly higher in migraine patients (103.15 pg/mL [IQR 70.98–146.34] vs. 69.43 pg/mL [IQR 53.04–91.85], p < 0.001), without significant difference between EM and CM patients and between patients with and without an attack at sampling (p = 0.235) (Table 1). This evidence concerns the gene GFAP and cutaneous mastocytosis.